Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Update

Anixa Biosciences, Inc. (NASDAQ:ANIX) was the target of a significant decline in short interest in October. As of October 31st, there was short interest totalling 421,900 shares, a decline of 28.9% from the October 15th total of 593,700 shares. Based on an average daily volume of 75,800 shares, the days-to-cover ratio is currently 5.6 days. Approximately 1.4% of the shares of the company are short sold.

Anixa Biosciences Trading Down 1.0 %

Shares of Anixa Biosciences stock traded down $0.03 during trading on Friday, reaching $3.10. The company’s stock had a trading volume of 48,347 shares, compared to its average volume of 109,327. The business’s fifty day moving average price is $3.27 and its 200-day moving average price is $2.99. Anixa Biosciences has a one year low of $2.14 and a one year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, September 6th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. Equities research analysts forecast that Anixa Biosciences will post -0.42 earnings per share for the current year.

Wall Street Analyst Weigh In

ANIX has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, September 17th. EF Hutton Acquisition Co. I raised shares of Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Institutional Trading of Anixa Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in ANIX. Virtu Financial LLC raised its position in shares of Anixa Biosciences by 47.2% during the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock worth $50,000 after purchasing an additional 5,183 shares during the period. Nations Financial Group Inc. IA ADV increased its holdings in Anixa Biosciences by 50.0% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock worth $50,000 after purchasing an additional 7,500 shares in the last quarter. Concorde Asset Management LLC acquired a new position in shares of Anixa Biosciences during the second quarter worth about $31,000. International Assets Investment Management LLC raised its position in Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the last quarter. Finally, Tyler Stone Wealth Management lifted its position in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares in the last quarter. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.